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Cigarette smoking and radiographic progression in rheumatoid
arthritis
Abstract
BACKGROUND: Smoking is a well-established environmental risk factor for the development of
rheumatoid arthritis (RA). However, it remains unclear whether smoking influences RA disease
progression and whether smokers have more radiographic damage progression than non-smokers over
time. OBJECTIVE: To compare the rates of radiographic damage progression in current smokers and
non-smokers in a large prospective RA cohort. METHODS: The SCQM-RA is a population-based
registry monitoring disease activity, radiographic damage and symptoms at regular intervals. All
patients in the SCQM-RA database with sequential plain radiographs were included. Joint erosions were
assessed in 38 hand and foot joints with a validated scoring method. The rate of erosion progression was
analysed using multivariate longitudinal regression models and adjusted for potential confounders.
RESULTS: 2004 RA patients with a mean of 3.6 sequential radiographs and 3.1 years of follow-up were
included. The 545 (27%) current smokers smoked on average 16 cigarettes per day and had a mean past
smoking exposure of 20.6 pack-years. Radiographic joint damage progressed at a similar rate in current
smokers and non-smokers (p = 0.26). However, smoking intensity was associated with a significant
inverse dose-response; heavy smokers (>1 pack-day) progressed significantly less than non-smokers or
moderate smokers (p<0.001). CONCLUSION: Radiographic joint damage progressed at an equivalent
rate in smokers and non-smokers. Furthermore, a significant trend was observed for reduced
radiographic progression and generally more favourable functional scores among heavy smokers,
suggesting that cigarette smoke does not accelerate RA disease progression.
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Abstract: 
Background: Smoking is a well-established environmental risk factor for the development of 
rheumatoid arthritis (RA). However, it remains unclear whether smoking influences RA 
disease progression and whether smokers have more radiographic damage progression than 
non-smokers over time. 
Objective: To compare the rates of radiographic damage progression in current smokers and 
non-smokers in a large prospective RA cohort. 
Methods: The SCQM-RA is a population-based registry monitoring disease activity, 
radiographic damage and symptoms by means of questionnaires at regular intervals. All 
patients in the SCQM-RA database with sequential plain radiographs were included. Joint 
erosions were assessed in 38 hand and foot joints with a validated scoring method. The rate of 
erosion progression was analyzed using multivariate longitudinal regression models and 
adjusted for potential confounders. 
Results: 2004 RA patients with mean of 3.6 sequential radiographs and 3.1 years of follow-
up were included. The 545 (27%) current smokers smoked on average 16 cigarettes per day 
and had a mean past smoking exposure of 20.6 pack-years. Radiographic joint damage 
progressed at a similar rate in current smokers and non-smokers (p=0.26). However, smoking 
intensity was associated with a significant inverse dose-response; heavy-smokers (> 1 pack-
day) progressed significantly less than non-smokers or moderate smokers (p<0.001). 
Conclusion: In contrast to our a priori hypothesis, radiographic joint damage progressed at 
an equivalent rate in smokers and non-smokers. Furthermore, we observed a significant trend 
for reduced radiographic progression and generally more favourable functional scores among 
heavy smokers, suggesting that cigarette smoke does not accelerate RA disease progression.  
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INRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes progressive 
joint destruction, disability and premature death. As a complex inflammatory disease, both 
genetic and environmental risk factors are thought to be important in its pathogenesis [1, 2]. 
Long-term outcomes such as severe disability and surgical joint replacement occur relatively 
late in the disease. The rate of progression of joint damage on radiographs is a measurable 
proxy for RA severity, representing cumulative disease activity for an individual patient. 
Many studies have shown that radiographic joint damage is associated with long-term loss of 
function, long-term disability [3, 4], employment status [5] and social security disability status 
[6]. Radiographic measures of joint damage are generally considered the ‘gold standard’ for 
treatment efficacy studies [7] and controlling progressive joint damage has become a goal for 
the management of RA [8].  
Smoking is the best-established environmental risk factor for the development of 
rheumatoid arthritis (RA) [9-19] and potential mechanisms are starting to be understood [2]. 
Some studies have suggested that smoking also influences RA disease severity [20-24], 
however this remains controversial [23]. In cross-sectional studies, smokers have higher 
concentrations of rheumatoid factor (RF) [21-23], more rheumatoid nodules [21-23, 25], 
lower grip strength [22], more functional disability [22], higher levels of disease activity [23] 
and more erosions on radiographs [20-23]. However, because of the cross-sectional design of 
these studies, no causal relationships have been established. In contrast, in longitudinal 
studies, current and past smokers had similar rates of radiographic damage progression [23, 
24, 26, 27], had less persistent synovitis [26] and were less likely to require total joint 
arthroplasty [28].  
To date, it remains unclear whether smoking influences disease severity or disease 
progression in established RA. In particular, we do not know whether current smokers have 
more radiographic damage progression than non-smokers over time, which might be another 
critical incentive for RA patients to quit smoking. The aim of this study was therefore to 
assess the influence of current smoking on the rate of radiographic damage progression in RA 
patients. Our a priori hypothesis was that cigarette smoking would accelerate the erosive 
disease process. 
METHODS 
Study population. The Swiss Clinical Quality Management program for RA (SCQM-
RA) is a longitudinal population-based cohort of RA patients. The program is under the 
auspices of the Swiss Society of Rheumatology, and aimed at improving the quality of care 
for RA patients by providing feedback on outcomes for individual patients to the physician 
(provider feedback) [29]. Rheumatologists are further motivated to enrol their patients in the 
SCQM-RA as they are allowed to deduct drug costs for enrolled patients from their global 
treatment expenditures, scrutinized by the health authorities. Currently more than two thirds 
of all practicing rheumatologists in Switzerland are contributing patients to the SCQM. 
Patients come from a wide range of settings: about 60% come from private practices, 20% 
from academic centres and 20% from non-academic centres. Because the recruitment is 
exclusively carried out by rheumatologists, those enrolled tend to have more severe disease 
[30], often treated with biologic therapies [31, 32]. The SCQM system requests at least yearly 
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assessments of disease activity, radiographic damage, antirheumatic therapy, 
sociodemographic factors and lifestyle characteristics, including cigarette smoking history..  
Study design. This is a longitudinal observational study of a population-based cohort of 
RA patients. The analysis included data collected between March 1996 and November 2005. 
The inclusion criteria were a diagnosis of RA by a rheumatologist and at least 2 consecutive 
sets of radiographs. Exclusion criteria were a missing smoking status or missing follow-up 
radiographs.  
Outcome variables. The study’s primary outcome was the progression of radiographic 
joint damage as measured by changes from baseline in radiographic damage scores. 
Radiographic damage was assessed prospectively by a single assessor on serial radiographs 
with a validated scoring system (Ratingen Score) according to a published method [33]. The 
scoring method is sensitive to change and less susceptible to ceiling effects in advanced 
disease because of a true ordinal rating scheme [34]. The reliability of this scoring method is 
excellent with an intraclass correlation coefficient (ICC) for intra-rater reliability of 0.8 to 0.9 
and an ICC for inter-rater reliability of 0.7 to 0.9 [33, 35]. The minimal detectable 
radiographic change for this method has been determined to be 3.3% of the maximum score 
[33]. The intra-rater reliability for the study assessor of these radiographs is good with an 
intraclass correlation coefficient (ICC) of 0.94 for a cross-sectional assessment and an ICC of 
0.71 for change scores. 
A secondary outcome of this study was the progression of functional disability as 
measured by change from baseline in the Stanford Health Assessment Questionnaire disability 
index [36](HAQ). The HAQ is a 20 item self-report questionnaire ranging from 0 to 3, which 
tends to increase slowly over time in RA (average of 0.03 units per year [6]). The HAQ is the 
most widely used functional status questionnaire in rheumatology and has been shown to 
predict work disability [37], joint replacement [37], medical costs [38] and mortality [39] in 
RA.  
Exposure variable and predictors. The exposure of interest for this study was current 
smoking. All patients were categorized as smokers or non-smokers based on current smoking 
status in the patient’s self-reported questionnaire. Patients discontinuing smoking or starting 
smoking during the observation period were also categorized as smokers. In order to explore a 
potential dose-response effect of smoking, we further stratified smokers into ‘heavy smokers’ 
(more than 1 pack/day) and ‘moderate smokers’ (one pack/day or less). Other important 
predictors of RA disease progression such as measures of disease activity, self-assessed 
symptom questionnaires, various disease characteristics, and demographic characteristics, 
were extracted from the database to be used in the analysis. We further determined the 
dominant antirheumatic treatment regimen utilized during the time-span in between 
consecutive radiographic assessments and used this variable to control the analysis for 
DMARD use. The dominant antirheumatic treatment was operationally defined as the 
regimen used during more then 50% of the follow-up period. 
Statistical Analysis. Based on previous studies with this dataset [31], we calculated that 
a sample size of 102 patients per group with an alpha error of less than 0.05 would provide 
90% power to detect a 2-sided difference of at least 1 Ratingen score units (0.5% of the 
maximum score) in radiographic damage progression per year, which represents a small 
difference.  
Baseline disease characteristics were compared between the two groups using one-way 
ANOVA for normally distributed continuous variables and the Kruskal-Wallis test for non-
normally distributed continuous variables. For dichotomous variables, Pearson’s Chi-square 
test was used to evaluate the significance of differences in proportions. Fewer than 5% of 
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covariates were sporadically missing; in order to minimize potential bias, we used the 
population average of the respective covariates as a substitute. 
Confounding was a concern in this study, as it is known from the literature that patients 
who smoke tend to present to their physicians with more severe RA. Because such differences 
may substantially influence disease progression, we used multivariate adjustment to overcome 
such confounding effects. Radiographic and functional disability progression was analyzed 
using generalized mixed models for longitudinal data [40]. We first selected the best fitting 
model without controlling for potential confounders (crude model). We verified that the 
multivariate normal assumption for longitudinal models was satisfied and examined whether 
time as a linear trend or as a polynomial function fit the data best. We then adjusted the 
analysis for differences in baseline disease characteristics. Rheumatoid factor, age, sex, 
DAS28, HAQ, disease duration and DMARD use were all considered confounders a priori 
and added into the model. We tested other covariates using a backwards stepwise selection 
approach. The final model was adjusted for differences in baseline damage scores, disease 
activity (DAS28), functional disability (HAQ), use of DMARDs and glucocorticoids, 
presence of rheumatoid factor, gender, age, disease duration and education level. Point 
estimates of the regression model were used to produce the result graphs (Figure 1). We also 
explored potential effect modification by sex, by presence of rheumatoid factor and by 
therapy with TNF inhibitors. All statistical tests were two-sided and evaluated at the 0.05 
significance level. The statistical analysis was performed with Stata version 9.2 for Windows 
(Stata Statistical Software, Texas, USA).  
RESULTS
 
Of the 3601 patients with rheumatoid arthritis in the SCQM-RA registry, a total of 2004 
RA patients with an average of 3.6 sequential X-rays and 3.1 years of follow-up met the study 
inclusion criteria (56%). All excluded patients (1597 patients) were missing follow-up 
radiographs. Because missing radiographic follow-up is generally related to a recent 
enrolment in the database (median enrolment in 2004 versus 2001 for study patients, p < 
0.0001), we assumed absent follow-up to be missing at random. The 545 (27%) current 
smokers consumed on average 16 cigarettes per day and had a mean past smoking exposure of 
20.6 pack-years. Five patients reported ceasing smoking and none reported starting smoking 
during the observation period. Smokers categorized as ‘heavy smokers’ (n=55) reported an 
average intake of 33 cigarettes/day and 27.7 years of smoking, compared to an average of 13 
cigarettes/day and 24.2 years of smoking for ‘moderate smokers’ (n=489). As expected 
smokers were predominantly male, younger with shorter disease durations and consequently 
less joint erosions at baseline (Table 1). Other important risk factors for disease progression 
such as rheumatoid factor seropositivity, anti-rheumatic therapy, glucocorticoid use, 
functional status and educational level did not differ significantly between smokers and non-
smokers. 
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Table 1: Baseline Patient Characteristics 
Disease characteristics Non-smokers  
(N = 1459) 
Moderate 
Smokers 
(N = 489) 
Heavy 
Smokers 
(N = 55) 
P † 
Age [years], mean (SD) 56 (13) 52 (13) 51 (10) 0.001 
Gender, male [%] 22 32 40 < 0.001 
Alcohol, regular [%] 54 68 69 < 0.001 
Disease Duration [years] 7.3 (2.8-14.3) 5.8 (2.2-12.4) 6.3 (2.7-10.1) 0.001 
ERO score [0–100] 3.3 (0.8.-13.4)  2.3 (0.5-9.1)  2.3 (0.2-7.3) 0.002 
Educational level [years]  13 (9-14) 13 (9-14) 13 (9-16) 0.61 
RF [%] 79 81 82 0.55 
Disease Activity (DAS28) 4.5 (3.4-5.6) 4.3 (3.3-5.3) 4.4 (3.7-5.2) 0.051 
Functional capacity (HAQ) 1.0 (0.5-1.6) 1.1 (0.5-1.6) 1.4 (0.8-1.8) 0.30 
DMARD use * 
-  Methotrexate, mono.° [%] 
-  Leflunomide, mono.°[%] 
-  Sulfasalzine, mono.° [%] 
-  Other DMARD, mono.° [%] 
-  DMARD combinations ‡ [%] 
-  Biologic therapies, mono.° [%] 
-  Biologic therapies, comb.# [%] 
-  None 
 
28 
7 
5 
5 
12 
12 
16 
15 
 
30 
6 
4 
5 
14 
11 
14 
16 
 
26 
5 
3 
3 
13 
12 
18 
20 
0.56 
 
 
 
 
 
 
Glucocorticoids ª [%] 42 42 40 0.72 
Follow-up [years], mean (SD)  3.1 (1.8) 3.0 (1.8) 3.1 (1.6) 0.29 
Legend Table 1: Results are indicated in Median and Interquartile Ranges (IQR), if not indicated 
otherwise. † Kruskal-Wallis test for non-normally distributed variables; Student T-test for normally 
distributed continuous variables; Chi square test for dichotomous variables. Education level = total 
number of years of school and college; disease duration = disease duration at first visit; ERO score = 
Percent of the maximum possible Ratingen Damage score; DAS28 = Disease activity Score based on 
28 joints; HAQ = Stanford Health Assessment Questionnaire disability index; * The DMARD 
percentages represent the proportion of person-time each DMARD was used during follow-up. ° 
mono. = monotherapy. ‡ Combination therapy = any combination of 2 or more conventional 
DMARDs; #
 
Biologic combination therapy = any combination of a TNF inhibitor or rituximab and a 
conventional DMARD ª Glucocorticoids = low dose glucocorticoids. 
 
Radiographic damage progression: No evidence for more rapid progression of 
radiographic joint damage was seen among smokers compared to non-smokers. In the crude 
analysis, unadjusted radiographic damage progressed by 2.75% (95% CI: 2.54-2.96) at 2 
years in non-smokers compared to 2.47% (95% CI: 2.10 – 2.79) in smokers (p = 0.14). In the 
fully adjusted model, radiographic damage progressed by 2.79% (95% CI: 2.59-3.02) at 2 
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years in non-smokers compared to 2.51% (95% CI: 2.14 - 2.89) in smokers (p = 0.26). 
However, we found an inverse dose-response effect for heavy smokers compared to moderate 
smokers and non-smokers (trend test, p < 0.001). Specifically, radiographic erosions evolved 
significantly more slowly in heavy smokers compared to non-smokers (p < 0.001), whereas 
erosive disease in moderate smokers progressed at a rate similar to that in non-smokers (p = 
0.65). In two years, heavy smokers progressed an average of 1.21% (95% CI: 0.23 – 2.25) of 
the maximum damage score, moderate smokers by 2.71% (95% CI: 2.35 – 3.06) and non-
smokers by 2.86% (95% CI: 2.65 – 3.07) (Figure 1a). In a sensitivity analysis, we examined 
current smoking exposure as a continuous variable and with an alternative categorization and 
found qualitatively the same inverse dose-response effect (data not shown). Analyses 
restricted to subgroups of patients with RF positive disease, male patients and patients treated 
with TNF inhibitors yielded qualitatively very similar results. The strongest predictors of 
radiographic damage progression were disease duration, baseline radiographic damage and 
RF.  
Progression of functional disability: To examine the consistency of the radiographic 
data, we repeated the analysis with the HAQ score as the outcome. Patients had a mean of 5.4 
sequential HAQ score assessments during the observation period. Overall, mean HAQ scores 
tended to improve somewhat during the first years of the observation (-0.034 at 1 year (95% 
CI: -0.025; -0.043) and -0.054 at 2 years (95% CI: -0.038; -0.070), related to the initiation of 
new anti-rheumatic therapies at the time of enrolment into the database (Figure 1b). As with 
the radiographic data, the evolution of HAQ scores did not differ significantly between 
smokers and non-smokers (crude analysis p = 0.36; adjusted p = 0.35). We found no 
significant inverse dose-response effect with functional disability in heavy smokers compared 
to moderate smokers and non-smokers (trend test, p = 0.68; ANOVA, p = 0.11). However, 
heavy smokers also tended to have more favourable HAQ scores than non-smokers, although 
the difference did not reach significance. At 2 years, heavy smokers improved their functional 
scores on average by -0.16 (95% CI: -0.05;-0.27), moderate smokers by -0.10 (95% CI: -
0.06;-0.14) and non-smokers by -0.11 (95% CI: -0.09;-0.13) (Figure 1b). We did not find any 
effect modification of smoking by gender, by RF positivity or by TNF inhibitor therapy. 
Strong predictors for functional disability were high baseline HAQ score, female gender, RF 
and lower educational levels. 
DISCUSSION
 
While smoking is a well-established environmental risk factor for the development of 
RA, in particular seropositive RA, its effects on RA severity are still controversial. In this 
large observational study, we found no difference in the progression of radiographic joint 
damage or functional disability between current smokers and non-smokers. We observed an 
unexpected inverse dose-response with current smoking intensity; heavy smokers had less 
radiographic disease progression than moderate and non-smokers. The evolution of functional 
capacity displayed a similar trend, although it did not reach significance. This suggests that 
smoking may be more important in the initiation of RA than in the perpetuation of the erosive 
disease process.  
Other studies have examined radiographic damage related to smoking status with 
conflicting results [21-24, 26, 27, 41]. All studies that have demonstrated significant 
associations between radiographic joint damage and smoking were cross-sectional analyses 
[21-23, 41]. Cross-sectional studies are unable to establish the temporality of events, limiting 
their ability to make causal inferences. For example, disease severity could influence smoking 
habits, which in turn would bias an association between smoking and disease severity in 
cross-sectional analyses. Furthermore, smoking is associated with socioeconomic factors and 
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disease characteristics that could confound the association with RA disease severity. In 
longitudinal studies examining the association between cigarette smoking and radiographic 
progression, no effect of overall current or past smoking has been seen [23, 24, 26, 27]. Some 
of these studies reported a dose-response with cumulative smoking exposure on radiographic 
damage [24], but others have not [23, 26]. Interestingly, the only other longitudinal study that 
examined the impact of current smoking, also described a possible inverse dose-response 
upon radiographic progression [26]. Furthermore, the authors of that study also found that 
current smokers had significantly fewer swollen joints over time [26]. Wolfe et al. 
unexpectedly found that past or present smoking was protective against requiring total joint 
replacement in RA [28]. Taken together, these results suggest that the discrepancy between 
published studies on the effect of smoking on RA severity may be related in part to study 
design (cross-sectional versus longitudinal). Our findings are in agreement with other 
longitudinal analyses examining the effect of smoking on radiographic progression [23, 24, 
26, 27]. The larger sample size of our observation may have allowed us to demonstrate a 
significant inverse dose-response with current smoking intensity. 
Functional disability correlates relatively well with long-term radiographic joint damage 
in established RA [41]. As with radiographic change, we did not find significant differences 
in the evolution of functional disability (HAQ scores) between current smokers and non-
smokers, nor did we see a significant dose-response effect. Others have made similar 
observations concerning functional capacity and smoking [24, 26], which might be due to the 
lower sensitivity to change of functional measures compared to radiographic outcomes. 
Overall changes in functional capacity over time were very small and not clinically significant 
[38]. 
Smoking is related in a dose-dependent fashion to RF and anti-CCP antibody titres, both 
in healthy individuals and in RA patients [2, 20, 21, 24, 42, 43]. Furthermore, a gene-
environment interaction has been reported between the HLA-shared epitope and cigarette 
smoking in determining the risk of seropositive RA [44]. It is hypothesized that smoking 
induces citrullination of certain peptides, which, in the presence of the shared-epitope, may 
lead to the expression of anti-CCP antibodies and the development of RA [1, 2]. In the present 
study, we explored a potential interaction between smoking and RF, since data concerning 
HLA shared epitope and the anti-CCP antibodies were not consistently available. We found 
no effect modification of the association between smoking and radiographic progression by 
the presence of RF, suggesting that this interaction may play a role in the pathogenesis of RA, 
but not necessarily in disease severity. Other biological effects of smoking have been 
hypothesized such as direct effects on the immune function [45]. It would seem logical to 
assume that the same mechanisms that intervene in disease susceptibility could also induce 
more severe forms of RA [21].  
The finding that heavy smokers have less radiographic progression was not expected. 
However, smoking has been reported to protect against the development and the severity of 
osteoarthritis [46-48] and demonstrated protective effects in several other inflammatory 
diseases such as ulcerative colitis or Kaposi sarcoma [26, 49-51]. The results of different 
clinical studies suggest that nicotine, one of the multiple components of tobacco, possesses 
anti-inflammatory properties. These regulatory effects are mediated by the α7 nicotinic 
acetylcholine receptor (α7 nAcR), which is expressed on macrophages and endothelial cells 
[52]. Indeed, acetylcholine released following stimulation of the vagus nerve and 
administration of agonists such as nicotine decreases the release of pro-inflammatory 
cytokines such as TNF-α by macrophages in experimental models [53]. Nicotine inhibits the 
expression of adhesion molecules induced by TNF-α, and blocks leukocyte migration in the 
carrageenan air pouch model. This inhibitory effect of nicotine in endothelial cells is mediated 
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by blocking the activation of NF-κB induced by TNF-α [52]. Recently, it has been shown that 
nicotine can dampen macrophage activation by stimulating the production of the suppressor 
of cytokine signalling (SOCS)3 [54], a member of a family of negative signalling regulators 
that exerts potent anti-inflammatory effects in experimental arthritis [55]. Another potential 
pathway through which nicotine can exert anti-inflammatory properties is spinal activation of 
the primary afferent nociceptor, which inhibits plasma extravasations in animal models of 
arthritis [56]. Currently, several trials testing therapeutic approaches targeting the α7 nicotinic 
receptor are ongoing [51, 57, 58]. Taken together, both clinical observations and results of 
experimental models, suggest that nicotine may exert protective effects in inflammatory 
diseases and thus, may support our finding in RA. 
Our study does have several limitations. Forty four percent of patients in the registry had 
no radiographic follow-up and were excluded. Study subjects without radiographic follow-up 
were overall similar in their socioeconomic and disease characteristics (data not shown), 
except for a higher proportion of smokers in subjects without radiographic follow-up (39% 
versus 27%, p < 0.001), but similar proportion of heavy smokers (11%, p= 0.71). Our results 
could be biased if missing radiographic follow-up were associated with both smoking and 
with more severe radiographic progression. We have several reasons to think that our results 
are not due to selection bias. First, the main cause for missing radiographic follow-up was 
recent enrolment in the database with insufficient time for subsequent radiographs (median 
enrolment in 2004 versus 2001 for those missing versus those not missing radiographic data, 
p < 0.0001). Secondly, while an association with smoking appears to exist, we have no 
indication that missing radiographic follow-up is related to a more severe disease progression. 
On the contrary, patients with more severe disease are likely to be evaluated more closely and 
regularly assessed by radiographs than patients with a more benign evolution, which would 
tend to bias these results towards the null. Thirdly, important prognostic factors of disease 
progression, such as disease activity (DAS28), functional capacity (HAQ) or estimated prior 
radiographic progression, did not differ significantly among smokers that were included and 
or excluded from this study. 
 We employed self-reported smoking exposure status, which may be prone to 
misclassification. While patients may under-report their daily tobacco consumption to please 
their physicians, it is highly unlikely that the current smoking status was differentially 
misclassified by levels of disease severity. We have not examined the impact of past smoking, 
which also has been associated with more severe disease in past studies [20, 24]. Because of 
the wording of our questionnaire, most current non-smokers did not report past smoking. 
Therefore, we felt that this information was probably unreliable and chose not to analyze it. 
Furthermore, cumulative cigarette exposure was highly correlated with current smoking 
intensity, making it difficult to dissociate the effect of past and current smoking. We also 
could not examine the influence of passive smoking, which was not assessed in the 
questionnaires. Nevertheless, the primary objective of this study was to examine 
pragmatically if current smokers had more rapid disease progression in established RA, 
independent of their past smoking history. While we were able to control the analysis for 
potential confounding by important prognostic factors such as RF, socioeconomic status, 
disease activity and duration, and drug therapies received, we cannot exclude the possibility 
of residual confounding or unmeasured confounding, nor dynamics such as a potential 
“survivor effect” in chronic smokers, such that the patients most affected by smoking have 
quit in the past. 
The main strength of our analysis is the use of a large, prospectively-followed, 
population-based RA cohort. As enrolment in the SCQM-RA database is determined by 
physician and treatment choices (patients on biologic therapy are preferentially enrolled), 
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there is little chance that smokers or non-smokers were differentially enrolled. Quantification 
of radiographic destruction was performed using validated and reproducible methods with 
high intra-rater and inter-rater correlations. The power of our study was sufficient to detect 
small differences in rates of radiographic progression and notably larger than other studies 
that have examined the effects of smoking on radiographic progression. We employed a 
longitudinal analysis accounting for therapies, socioeconomic factors and other important 
confounders.  
In conclusion, no difference was demonstrated in the progression of radiographic joint 
damage or functional disability between current smokers and non-smokers in this cohort of 
patients with established RA. However, an inverse dose-response emerged with smoking 
intensity. Heavy smokers demonstrated significantly less radiographic disease progression 
than mild- and non-smokers. Overall, this suggests that smoking may be more important in 
the initiation of RA than in the perpetuation of the erosive disease process. Possibly high 
levels of nicotine exposure could have anti-inflammatory effects, with beneficial 
consequences on RA disease progression. However, global health risks associated with 
smoking are much greater than those potential benefits. In particular, the cardiovascular 
hazards of smoking certainly outweigh the potential anti-inflammatory benefits of nicotine. 
Further research is needed to understand the impact of cigarette smoking on human immunity 
and identify the effects of tobacco exposure on RA disease outcomes.
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Legend Figure1: 
Figure1 A represents radiographic joint damage progression (=ERO) over time. The 
vertical lines represent the 95% confidence interval of the mean. The progression trajectories 
depicted are adjusted for differences in baseline differences in baseline damage scores, 
disease activity (DAS28), functional disability (HAQ), use of DMARDs and glucocorticoids, 
presence of rheumatoid factor, gender, age, disease duration and education level (=adjusted 
model). ERO score [%] represents the percentage of maximum possible damage of the 
Ratingen erosion score and corresponds to the average proportion of joint surface damaged 
by erosions. 
Figure 1 B represents progression of functional disability (=HAQ) over time. The 
vertical lines represent the 95% confidence interval of the mean. The progression trajectories 
depicted are adjusted for differences in baseline differences in baseline functional disability 
(HAQ), disease activity (DAS28), use of DMARDs and glucocorticoids, presence of 
rheumatoid factor, gender, age, disease duration and education level (=adjusted model). 
HAQ score from the Stanford Health Assessment Questionnaire ranges from 0 to 3, where 3 
represents the maximum possible disability. 
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Figure 1:  Progression of radiographic joint damage (A) and functional disability 
(B) in non-smokers, moderate smokers and heavy-smokers
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